COVID-19 vaccine boosters could mean billions for drugmakers
Drugmakers aren’t the only businesses that could see a windfall from delivering boosters. Drugstore chains CVS Health and Walgreens could bring in more than $800 million each in revenue.
Drugmakers aren’t the only businesses that could see a windfall from delivering boosters. Drugstore chains CVS Health and Walgreens could bring in more than $800 million each in revenue.
The coronavirus remains the dominant variable around how the U.S. economy will do for the rest of the year and into 2022, according to National Association of Business Economists.
A panel of health care experts in Indianapolis on Friday endorsed President Biden’s order that all businesses with more than 100 employees require their workers to be immunized or face weekly testing.
The state has released the latest statistics for so-called breakthrough cases, hospitalizations and deaths.
Under the new guidelines, the single booster dose can be administered at least six months after completion of the second dose and applies only to individuals who previously received the Pfizer vaccine.
CDC Director Dr. Rochelle Walensky signed off on a series of recommendations from a panel of advisers late Thursday, but she also included one recommendation that the panel had rejected.
Advisers to the Centers for Disease Control and Prevention said boosters should be offered to people 65 and older, nursing home residents and those ages 50 to 64 who have risky underlying health problems.
More than 3.23 million Hoosiers had been fully vaccinated against COVID-19 as of Thursday after a daily increase of 4,998.
Now that schools have welcomed students back to classrooms, they face a new challenge: a shortage of teachers and staff the likes of which some districts say they have never seen.
However, more regulatory hurdles lie ahead before the dispensing of boosters can begin.
Last month, United set a deadline of Sept. 27–next Monday–for its 67,000 U.S.-based employees to get vaccinated or face termination.
The increasingly lethal turn has filled hospitals, complicated the start of the school year, delayed the return to offices and demoralized health care workers.
The latest shortage is another painful reminder that the U.S. has yet to successfully manage its COVID-19 testing arsenal, let alone deploy it in the type of systematic way needed to quickly crush outbreaks in schools, workplaces and communities.
More than 3.21 million Hoosiers had been fully vaccinated against COVID-19 as of Tuesday after a daily increase of 6,838.
Regulators would have to authorize Johnson & Johnson booster shots before the public could receive them.
The travel bans had become the source of growing geopolitical frustration, particularly among allies in the United Kingdom and European Union.
The Indiana State Department of Health on Monday reported the latest COVID-19 figures related to schools, which showed a rise in student cases of 4,499
The new policy replaces a patchwork of travel restrictions first instituted by President Donald Trump last year and tightened by Biden last year that restricted travel by non-citizens to the United Kingdom, European Union, China, India and other countries.
While youngsters are at lower risk of severe illness or death than older people, more than 5 million children in the U.S. have tested positive for COVID-19 since the pandemic began and at least 460 have died, according to the American Academy of Pediatrics.
Data about booster shots for those who had received the Moderna or Johnson & Johnson vaccines could be a few weeks away from being reviewed, days after an FDA panel approved booster shots for a limited population of those who had received the Pfizer-BioNTech vaccine.